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Summary To elucidate the role of ras gene mutations during the early stage of colorectal tumour progression, K-ras gene mutations were
analysed in 32 benign adenomas and 36 adenomas with focal carcinoma in the colorectum by microscraping of histologically pure regions
from tissue sections, polymerase chain reaction-restriction fragment length polymorphism and in part by direct sequencing. Several regions
were scraped out and analysed when an adenoma contained areas with different grades of dysplasia. Thefrequencies of K-rasgene mutation
in mild dysplasia, moderate dysplasia and focal carcinoma were 19% (7/36), 51% (25/49) and 39% (14/36) respectively. The K-ras gene
status was heterogeneous in 4 of the 11 benign adenomas from which multiple samples were obtained, and mutations were always found in
the regions with more advanced dysplasia in these adenomas. Thirteen of the 36 adenomas with focal carcinoma showed heterogeneity of
mutations between the adenoma region and the focal carcinoma. Seven of which had mutations only in the adenoma region. These findings
indicated that the K-rasgene mutations occur during the late stage of adenoma progression and may confer a more advanced morphological
phenotype of adenoma, but these mutations are not mainly involved in malignant transformation from adenoma to carcinoma.
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It is widely accepted that colorectal carcinogenesis involves a
pathway called the adenoma-carcinoma sequence. Thus, adenoma
originating from normal colonic mucosa could develop with an
increase in atypism and finally transform into carcinoma. Recent
advances in molecular biology have provided some direct
evidence that colorectal tumorigenesis proceeds through a series
of genetic alterations, including the activation of ras (Bos et al,
1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and
Loeb, 1989) and inactivation of the tumour-supressor genes p53
(Baker et al, 1989), DCC (Fearon et al, 1990), MCC (Kinzler et al,
1991a) and APC (Groden et al, 1991; Kinzler et al, 1991b;
Nishisho et al, 1991).
Ras gene mutations are present in about one-half of colorectal
tumours, and most of them are detected in K-ras codons 12 or 13
(Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988). A
positive correlation between the incidence ofras mutations and the
development of adenoma in terms of size or histological atypism
suggests that ras mutations are involved in adenoma progression
(Vogelstein et al, 1988; Miyaki et al, 1990; Boughdady et al, 1992;
Ichii et al, 1993; Soh et al, 1993). However, it has not been clearly
demonstrated whether ras mutations directly confer a more
advanced phenotype or are simply likely to occur more frequently
in advanced adenomas than in those that are smaller or have a
milder dysplasia (Fearon, 1993).
On the other hand, ras gene mutations are thought to be weakly
associated with malignant conversion from adenoma to carcinoma
because the frequency of ras mutations among advanced cancers
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is similar to that among adenomas with advanced dysplasia
(Vogelstein etal, 1988; Boughdady etal, 1992; Ichii etal, 1993; Soh
et al, 1993). On the contrary, otherinvestigators have suggested that
ras gene mutations are involved in tumour progression through
cooperation withpS3 gene alterations (Hinds etal, 1990; Shaw etal,
1991; Bell et al, 1993), or that ras gene mutation itselfmay play a
critical role (Shirasawa et al, 1993) in colorectal tumorigenesis.
Thus, the role of ras gene mutations in the conversion from
adenoma to carcinoma in the colorectum remains unclear.
Moreover, almost all of the above findings were derived from
experiments using accumulated samples of adenoma and carci-
noma orcell lines. These investigations may provide some clues to
the general aspects of gene alterations in colorectal tumours, but
the actual pathway of tumour progression may not be exactly the
same in each sample.
To elucidate the relationship between ras gene mutations and
grade ofdysplasia, we examined K-ras gene mutations in colorectal
adenomas with various grades of dysplasia by means of micro-
scraping from each sample and polymerase chain reaction (PCR)-
based analysis. We specifically collected tissue samples that
consisted of histopathologically pure subpopulations of mild
dysplasia, moderate dysplasia or focal carcinoma. In the present
study, we use the term 'focal carcinoma' to describe a cancerous
region localized in an adenoma, including severe dysplasia and
intramucosal carcinoma. Malignant conversion is thought to have
just occurred in these regions, and adenomas with focal carcinoma
are thought to be ideal materials foranalysing the genetic alterations
in colorectal carcinogenesis based on the adenoma-carcinoma
sequence. Moreover, we scraped several regions from adenomas
when they consisted of areas with different grades of dysplasia to
obtain direct information about the relationship between K-ras gene
mutations and adenoma progression in each case.
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Figure 1 Representative colorectal adenomas stained with haematoxylin and eosin. (A), Before and (B) after microscraping with a needle from case 96.
Location of A1, A2and A3 is indicated in B. (C) 96 A,, mild dysplasia. (D) 96A2, moderate dysplasia. (E) 96 A3 appeared more advanced than another region of
moderate dysplasia (96 A2). Before (F) and after (G) microscraping from a focal carcinoma (severe dysplasia, case 003). Original magnification: A and B 9 x;
C-E, 180 x; F and G, 60 x. (H) Results of PCR-RFLP analysis of these samples. Mutations in K-ras codon 12 were detected in C3 A and 96 A3 Details of
PCR-RFLP are described in Materials and methods
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Table 1 List of individual tumours according to the histological grade and status of the K-rasgene
K-ras mutationc K-ras mutationc
Case Age Sex Sites Diameter Dysplasiab
no. (years) (mm)
(a) Adenomas with mild dysplasia
56b 44 M S 20 Mild
61 56 M R 15 Mild
67 61 M S 16 Mild
68 72 F R 10 Mild
70 59 M D 10 Mild
73 51 M R 11 Mild
79 54 M T 11 Mild
80 70 M S 16 Mild
82 70 M S 11 Mild
86 80 M D 15 Mild
93 54 M S 11 Mild
71 50 M S 20 Mild
74 71 M S 11 Mild
(B) Adenomas with moderate dysplasia
65 55 M T 13 Moderate
76 59 M R 10 Moderate
94 45 M S 14 Moderate
57b 46 M C 25 Moderate
58 77 M T 17 Moderate
69 64 M D 16 Moderate
78 54 M R 15 Moderate
64 44 M R 15 Moderate
(C) Adenomas with various grades ofdysplasia
75 53 M R 17 Al Mild
A2 Moderate
77 49 F D 10 Al Mild
A2 Moderate
81 54 M R 12 Al Mild
A2 Moderate
92 46 F S 15 Al Mild
A2 Moderate
97 70 M S 14 Al Mild
A2 Moderate
72 67 M S 12 Al Mild
A2 Moderate
85 80 M D 11 Al Mild
A2 Moderate
89 56 F S 17 Al Mild
A2 Moderate
A3 Moderate*
90 79 M D 10 Al Mild
A2 Moderate
91 47 M S 19 Al Moderate
A2 Moderate*
96 71 M UnknownUnknown Al Mild
A2 Moderate
A3 Moderate*
(D) Adenomas with focal carcinoma
33 54 M S 15 A Moderate
C
38 69 M R 10 A Moderate
C
47 59 F R 18 A Moderate
C
50 51 M A 10 A Moderate
C
49 69 M S 8 Al Mild
A2 Mild
C
31 54 M R 16 A Mild
C
34 74 M R 12 A Mild
C
36 60 M D 10 A Moderate
C
Codon Codon Case Age Sex Sitea Diameter Dysplasiab Codon
12 13 no. (years)
37 60
53 62
54 50
OCI 65
OC6 53
46 Unknown
OC2 49
11 55
16 79
OC4 61
+
M D
M R
M R
F S
M R
F S
F R
M R
M S
(mm)
13
15
40
15
9
11
9
7
15
26 65 M S 16
8 63
12 59
OC3 53
35 45
44 52
OC5 57
42 64
27 59
48 54
7 48
30 45
39 54
40 45
41 45
52 69
57 57
51 57
M A
M R
M R
F S
F R
M T
M S
M S
M R
F S
F R
M S
F D
F D
F R
M R
M R
9
25
14
25
10
5
4
12
26
16
16
13
15
12
12
11
3
A Mild
C
A Moderate
C
A Moderate
C
A Mild
C
A Moderate
C
Al Moderate
A2 Moderate
C
A Moderate
C
A Mild
C
A Moderate
C
Al Mild
A2 Moderate
C
Al Mild
A2 Moderate
C
A Moderate
C
A Moderate
C
A Moderate
C
A Moderate
C
A Mild
C
A Moderate
C
A Mild
C
A Moderate
C
A Moderate
C
A Moderate
C
A Moderate
C
A Moderate
C
A Moderate
C
A Mild
C
A Mild
C
A Moderate
C
A Moderate
C
aSite, site of the colorectum. R, rectum; S, sigmoid colon; D, descending
colon; T, transverse colon; C, caecum. bDysplasia, dysplasia of
microscopically scraped-out regions. Mild, mild dysplasia; moderate,
moderate dysplasia; moderate*, apparently more advanced compared with
the adjacent region with moderate dysplasia but could not be diagnosed as
severe dysplasia; C, focal carcinoma. Multiple regions cut out from the same
adenoma were expressed asAl and A2* cK-ras mutation, K-rasgene
mutations in codon 12 or 13:-, negative; +, positive.
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MATERIALS AND METHODS
Tissue samples and DNA extraction
Among the colorectal polyps resected endoscopically or surgically
in Osaka University Hospital or Osaka National Hospital, 32
benign colorectal adenomas (mild or moderate dysplasia) and 36
adenomas with focal carcinomas were investigated. We selected
32 benign adenomas of 10 mm or more in size, because they
should consist of various areas with different grades of dysplasia.
In fact, we obtained such heterogeneous regions from 11 out of 32
cases of benign adenomas. On the other hand, 36 adenomas with
focal carcinoma were collected regardless of size. All of the
samples were fixed immediately after resection by microwave
irradiation and embedded in paraffin, as we described (Kawasaki
et al, 1992; Ohue et al, 1994).
Two 8-gm sections were prepared for DNA extraction and an
adjacent 4-gm section was stained with haematoxylin and eosin
for histological examination. After the grade of dysplasia in each
region was histologically judged, identical regions were scraped
out from 8-gm sections. These sections had been stained only with
eosin, rinsed with water and dried up. For visualization, 2-5 ,ul of
70% ethanol was dropped on the tissue section and samples were
scraped out by hand manipulation with a sterile needle under
microscopic observation. These sections after scraping samples
were then stained by haematoxylin and observed to confirm that
A
M U D 7 8 11 35 48 30 51
,-c ACAC ACl ACAC
M
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B
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Figure 2 PCR-RFLP assay for detecting K-ras gene mutation in adenomas
with focal carcinoma. (A) Detection of mutations in codon 12. Inner PCR
products were digested with BslNI and separated by 12% polyacrylamide gel
electrophoresis. Wild-type and mutant fragments are represented by 114-
and 143-bp fragments respectively. Mutant bands are evident in lanes 8A,
11A, 48A, 48C, 30A, 51A and 51C. (B) Detection of a mutation in codon 13.
The K-ras codon 13 aspartate mutation was screened by digesting inner
PCR products with Hphl, by which the mutant fragment was cleaved to 114-
and 43-bp fragments, whereas the wild-type fragment remained undigested.
Mutant bands are evident in lanes 7A, 7C, 35C and 30C. The numbers
shown above the sample lanes correspond to the case numbers in Table 1.
A, adenoma; C, focal carcinoma; M, 0X174/ Haelll DNA marker; U and D,
undigested and digested PCR product of SW480 (A) and HCT 116 (B) DNA.
Note that 30A and 30C exhibit mutations in different codons
only desired regions were scraped out (Figure IF and G). Each
sample was obtained from histopathologically pure subpopula-
tions of mild dysplasia, moderate dysplasia or focal carcinoma.
From 11 benign adenomas consisting of various regions of
different grades of dysplasia, each region was separately scraped.
From 36 adenomas with focal carcinoma, regions of the focal
carcinoma and the adjacent adenoma were separately scraped.
Among the regions with moderate dysplasia, there were three
regions that had an apparently more advanced area compared with
the adjacent region with moderate dysplasia, but which could not
be diagnosed as severe dysplasia. We distinguished these regions
as moderate*, as shown in Table IC, and these regions were sepa-
rately scraped out (Figure lE). The areas of the scraped regions
varied from 0.04 to 16 mm2. These samples contained 5-20%
normal cells. Finally, we scraped out 36 regions ofmild dysplasia,
49 of moderate dysplasia and 36 of focal carcinoma from 32
benign adenomas and 36 adenomas with focal carcinoma
(Table 1). Subsequently, these samples were deparaffinized with
xylene and digested with proteinase K. DNA was purified by
phenol-choloroform extraction and ethanol precipitation, as
described (Sambrook, 1989; Ohue et al, 1994), then dissolved in
50 gl ofdistilled water.
Detection of K-ras gene mutations
We employed nested PCR in order to amplify DNA fragments effi-
ciently with only a small amount of template DNA. According to
the known base sequence data for the K-ras gene (McGrath et al,
1983), we designed outer primers to produce a 271-bp fragment,
which included the whole sequence of the 157-bp inner PCR
product. The outerprimers were 5'-CTGTGGAGTATTTGATAGT-
3' (upstream) and 5'-GAAAATGGTCAGAGAAACCT-3' (down-
stream).
The primers for inner PCR were designed for a mutation-
specific PCR-restriction fragment length polymorphism (RFLP)
to detect point mutations in K-ras codons 12 and 13 (Jiang et al,
1989). Outer PCR was performed in 25-gl volumes with 1 gl of
DNA solution and 100 ng ofprimers in 10% dimethyl sulphoxide
(DMSO), 67 mm Tris-HCl (pH 8.8), 6.7 mm magnesium chloride,
16.6 mM ammonium sulphate, 10 mM P-mercaptoethanol, 6.7 mM
EDTA and 1.5 mm dNTPs containing 2.5 units of Thermus
aquaticus (Taq) DNA polymerase (Boehringer Mannheim,
Penzberg, Germany). PCR reactions consisted of an initiation
cycle (5 min at 940C, 3 min at 55°C and 2 min at 720C), repeated
cycles (35 cycles of 1 min at 94°C, 1 min at 550C and 1 min at
72°C) and a termination cycle (1 min at 94°C, 2 min at 55°C and
3 min at 72°C).
One per cent ofthe outerPCR product was used as the template
DNA for the second round inner PCR. The conditions of inner
PCR were the same except the annealing temperature was 57°C.
The inner PCR products were purified by phenol-chloroform
extraction and ethanol precipitation, digested with restriction
endonuclease BstNI or HphI, separated by 12% polyacrylamide
gel electrophoresis and visualized by ethidium bromide staining
(Figure 2).
In each PCR, the DNA ofthe SW480 colon carcinoma cell line,
which is hemizygous for a mutation in K-ras codon 12 (Capon et
al, 1983), and the DNA ofthe HCT116 colon carcinoma cell line,
which contains a K-ras codon 13 aspartate mutation (Jiang et al,
1989), were used as templates for positive controls. Sterilized
water was used instead of template DNA and run in parallel in
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Table 2 K-ras gene mutations in 11 benign adenomas with various grades of
dysplasia
K-ras gene mutationa No. of cases
Heterogeneity evident
mild(-) moderate(+) 1
mild(-) moderate(-) moderate*(+) 2
moderate(-) moderate*(+) 1
Heterogeneity not apparent
mild(-) moderate(-) 5
mild(+) moderate(+) 2
a K-ras gene mutation, status of K-rasgene mutation in the 11 benign
adenomas with areas of various grades of dysplasia: mild, mild dysplasia;
moderate, moderate dysplasia; moderate*, apparently more advanced
compared with the adjacent region with moderate dysplasia but could not be
diagnosed as severe dysplasia; (-), mutation negative; (+), mutation positive.
A
Case 39
Adenoma
G A C T
Focal carcinoma
G A C T
iG
G-+A
Codon 12
Table 3 Status of K-ras gene mutation in 36 adenomas with focal carcinoma
K-ras gene mutation' No. of cases
A(-) C(-) 15
A(+) C(+) 10
A(-) C(+) 4
A(+) C(-) 7
aK-rasgene mutation, status of K-ras gene in focal carcinoma and adjacent
adenoma in the same case: A, adenoma; C, focal carcinoma; (-) mutation
negative; (+) mutation positive.
Table 4 Type of K-rasgene mutation in ten colorectal adenomas with focal
carcinoma
Case no. Codon Type of mutation
7A 13 GAC
C 13 GAC
27A 13 GAC
C 13 GAC
30A 12 ND
C 13 ND
39A 12 GAT
C 12 GTT
40A 12 GAT
C 12 GAT
41A 12 GAT
C 12 GAT
48A 12 GAT
C 12 GAT
51A 12 AGT
C 12 AGT
52A 12 GTT
C 12 GTT
57A 12 NA
C 12 NA
NA, not available; ND, not done; A, adenoma; C, focal carcinoma.
agarose gels in each PCR as the negative control. PCR, enzyme
digestion and electrophoresis proceeded at least twice to confirm
the reproducibility ofthe results.
B
Case 40
Adenoma
G A C T
Focal carcinoma
G A C T
G
G-+A
T
Codon 12
iG
G-+A
T
Codon 12
Figure 3 Sequencing of the inner PCR products. (A) Case 39 exhibits a G-
to-A base change in the adenoma and a G-to-T base change in the focal
carcinoma at the second position of K-ras codon 12. (B) Case 40 exhibits a
G-to-A base change at the second position of K-ras codon 12 in both the
adenoma and the focal carcinoma
Sequencing of PCR products
Some of the K-ras gene mutations in adenomas with focal carci-
noma were determined by direct sequencing using a Takara Taq
cycle sequencing kit (Takara Shuzo, Kyoto, Japan), according to
the manufacturer's protocol.
RESULTS
Frequency of K-ras gene mutation in each grade of
dysplasia and in focal carcinomas
We scraped out 36 regions of mild dysplasia, 49 of moderate
dysplasia and 36 offocal carcinoma from 32 benign adenomas and
36 adenomas with focal carcinoma, as shown in Table 1. The
frequencies of K-ras gene mutation in mild dysplasia, moderate
dysplasia and focal carcinoma were 19% (7/36), 51% (25/49) and
39% (14/36) respectively. There was a statistically significant
difference in the frequency ofK-ras mutations between the regions
of mild and moderate dysplasia (P = 0.034, Fisher's exact test).
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K-ras gene mutations in 11 benign adenomas with
different grades of dysplasia
Several regions were scraped out from 11 benign adenomas that
contained at least two areas with different grades of dysplasia
(Table IC and Table 2). Among these adenomas, four showed
heterogeneity of the K-ras gene mutations and these were found
only in the regions with more advanced dysplasia. Case 90
contained a mutation in the region of moderate, but not mild
dysplasia, and three others (cases 89,91 and 96) had a mutation in
the regions with apparently more advanced dysplasia compared
with the adjacent regions of moderate dysplasia (represented as
moderate*). Heterogeneity of the K-ras gene was not evident in
the seven other benign adenomas.
Relationship between malignant conversion and K-ras
gene mutation
We divided the 36 adenomas with focal carcinoma, listed in Table
1D, into four groups according to the K-ras gene status in the
adenoma regions and the focal carcinoma regions (Table 3). Seven
had a mutation only in the adenoma region and four harboured a
mutation only in the focal carcinoma. Ten had a mutation in both
the adenoma region and the focal carcinoma region. However, in
case 30, the mutation in the adenoma region was detected in codon
12 and that in the focal carcinoma region was in codon 13 (Figure
2). We then determined the type of K-ras mutation in the
remaining nine cases by sequencing (Figure 3, Table 4). All ofthe
point mutations detected by sequencing were found in the same
codon by means of PCR-RFLP. Seven cases had the same type of
mutation in both the adenoma and carcinoma regions, but case 39
had a different type (case 57 could not be sequenced owing to limi-
tations in the amount of the DNA samples.). We could not detect
K-ras gene mutations in either adenoma regions or focal carci-
nomas in the remaining 15 cases.
Finally, the K-ras gene mutations were heterogeneous in 13 of
36 adenomas with focal carcinoma.
DISCUSSION
Several investigators have reported that the frequency of K-ras
gene mutations in colorectal adenoma is related to the grade of
dysplasia (Vogelstein et al, 1988; Miyaki et al, 1990; Boughdady
et al, 1992; Ichii et al, 1993; Soh et al, 1993). Also in this study, the
frequency of K-ras mutation was obviously higher in the regions
with moderate dysplasia than in the regions with mild dysplasia.
Our methods, including microscraping of tissue samples from
histologically pure subpopulations with different grades of
dysplasia should provide more precise information about the
contribution of K-ras gene mutations to the progression of
colorectal tumours: from mild to moderate dysplasia and from
adenoma to carcinoma.
Four of the 11 benign adenomas with various regions of
different dysplasia exhibited heterogeneous K-ras gene mutations.
Furthermore, mutations were found only in the regions with more
advanced dysplasia (Table 2). In addition, no adverse conditions,
such as mild(+) moderate(-), were found in this study. This
suggests that adenoma cells with K-ras gene mutations form a
novel clonal expansion, which always appeared with more
advanced dysplasia in this study. Therefore, we speculate that K-
ras gene mutations contribute to a more advanced morphological
phenotype during the late stages of adenoma progression. How-
ever, several reports of a high incidence of K-ras gene mutations
in aberrant crypt foci, which are histologically not dysplastic but
hyperplastic, suggest that a K-ras gene mutation alone cannot
confer dysplastic change (Pretlow et al, 1993; Smith et al, 1994).
To clarify whether or not the non-neoplastic epithelial cells with a
ras mutation develop into adenoma, further cell biological studies
are required.
With regard to the relationship between the ras gene and malig-
nant conversion, several investigators have claimed that ras gene
mutations do not contribute to the malignant transformation from
adenoma to carcinoma, because the frequency ofK-ras gene muta-
tion is similar in adenomas with advanced dysplasia and in carci-
nomas of the colorectum (Vogelstein et al, 1988; Boughdady et al,
1992; Ichii et al, 1993; Soh et al, 1993). The microanalysis in this
study enabled us to compare the mutational status of the ras gene
in the focal carcinoma with that in the adjacent background
adenoma in individual cases, thus providing some direct informa-
tion about the role of K-ras gene mutations in malignant transfor-
mation. Seven cases had the same type of K-ras gene mutation in
the adenoma and focal carcinoma (Table 4). A K-ras gene muta-
tion, which had already occurred in the adenoma region, might
simply have been inherited by the focal carcinoma in these cases.
Seven cases had K-ras mutations in the adenoma, but not in the
focal carcinoma regions [represented as A(+) C(-)], and the focal
carcinomas in these cases must have developed from an adenoma
cell without K-ras mutations although there was another subpopu-
lation with a K-ras mutation in the same case. These findings
showed that a subpopulation of an adenoma with a K-ras gene
mutation is not always the most progressive clone that will form a
focal carcinoma. Among these examples ofA(+) C(-), case 26 and
OC4 contained regions with mild dysplasia, moderate dysplasia
and focal carcinoma (Table 1D), and K-ras gene mutations were
found only in the region with moderate dysplasia. Although K-ras
gene mutations could confer the progression from mild to
moderate dysplasia, focal carcinomas were derived from regions
without K-ras mutations in these cases. In four cases with A(-)
C(+), K-ras gene mutations might make some contribution to the
malignant transformation. Overall, we concluded that K-ras gene
mutations do not contribute directly to the malignant transforma-
tion from adenoma to carcinoma. In this respect, p53 gene alter-
ation is the most probable candidate contributing to the malignant
conversion, as we reported (Ohue et al, 1994).
Finally, the K-ras gene was heterogeneous in four of the 11
benign adenomas with various regions of different grades of
dysplasia and in 13 of the 36 adenomas with focal carcinoma.
Although the precise frequency remains unclear, heterogeneity of
the K-ras gene is a very common event in colorectal adenomas. K-
ras gene mutations might not be the initial event, but rather occur
during adenoma progression resulting in the heterogeneous status.
As reported previously,APC mutations already occur in very small
adenomas and can be the initiating alteration in the colorectal
adenoma formation (Powell et al, 1992). K-ras gene heterogeneity
in colorectal adenoma has also been shown in four of seven
colorectal adenomas (Shibata et al, 1993). The present findings are
in line with their report, although we increased the number of
samples and the variety to include focal carcinomas.
Furthermore, the microanalysis of colorectal adenomas with
different grades of dysplasia used in this study is thought to be a
very useful means of clarifying the genetic alteration involved in
colorectal tumorigenesis.
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